US › Healthcare

Skye Bioscience, Inc. Common Stock (SKYE)

US · Healthcare · Biotechnology

$0.57-1.57%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-12.5M
Profit YoY
-12.7%
EPS
$-0.32
EPS estimate
$-0.32

EPS came in at -0.32 against a street estimate of -0.32 — a beat of 0.0%.

Key statistics

Market cap
$20.0M
Forward P/E
0.0
P/B
2.22
Book value
$0.26
EPS (TTM)
$-1.45
52-week high
$4.99
52-week low
$0.56
50-day MA
$0.70
200-day MA
$0.91
Beta
2.94

Analyst view

Analysts rate Skye Bioscience, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $7.33.

Shareholding

Insiders
1.17%
Institutions
46.00%

Largest institutional holders

FundStake
5AM Venture Management, LLC27.56%
Versant Venture Management LLC5.72%
Baker Bros Advisors LP4.48%
Vanguard Group Inc2.51%
Vanguard Capital Management, LLC2.18%
Sphera Funds Management Ltd.1.93%
BlackRock Inc0.81%
Geode Capital Management, LLC0.79%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Skye Bioscience, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.